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Background:Mechanisms of cardiac hypertrophy in states of insulin resistance/high insulin remain poorly understood.
Results: In response to high insulin, myocardin/SRF expression in cardiac myoblasts is related to the development of cardiac
myoblast hypertrophy.
Conclusion:Myocardin acts, with Nuclear Factor-B, as a nuclear effector of insulin, promoting cardiac hypertrophy.
Significance: Understanding these mechanisms may help designing strategies to prevent diabetic cardiomyopathy.
Hyperinsulinemia contributes to cardiac hypertrophy and
heart failure in patients with themetabolic syndrome and type 2
diabetes. Here, high circulating levels of tumor necrosis factor
(TNF)- may synergize with insulin in signaling inflammation
and cardiac hypertrophy.We testedwhether high insulin affects
activation of TNF--induced NF-B and myocardin/serum
response factor (SRF) to convey hypertrophy signaling in car-
diac myoblasts. In canine cardiac myoblasts, treatment with
high insulin (108 to 107 M) for 0–24 h increased insulin recep-
tor substrate (IRS)-1 phosphorylation at Ser-307, decreased
protein levels of chaperone-associated ubiquitin (Ub) E3 ligase
C terminus of heat shock protein 70-interacting protein (CHIP),
increased SRF activity, as well as -myosin heavy chain (MHC)
and myocardin expressions. Here siRNAs to myocardin or
NF-B, as well as CHIP overexpression prevented (while
siRNA-mediated CHIP disruption potentiated) high insulin-in-
duced SR element (SRE) activation and -MHC expression.
Insulin markedly potentiated TNF--induced NF-B activa-
tion. Compared with insulin alone, insulinTNF- increased
SRF/SRE binding and -MHC expression, which was reversed
by the NF-B inhibitor pyrrolidine dithiocarbamate (PDTC)
and by NF-B silencing. In the hearts of db/db diabetic mice, in
which Akt phosphorylation was decreased, p38MAPK, Akt1,
and IRS-1 phosphorylation at Ser-307 were increased, together
with myocardin expression as well as SRE and NF-B activities.
In response to high insulin, cardiac myoblasts increase the
expression or the promyogenic transcription factors myocar-
din/SRF in a CHIP-dependent manner. Insulin potentiates
TNF- in inducing NF-B and SRF/SRE activities. In hyperin-
sulinemic states, myocardin may act as a nuclear effector of
insulin, promoting cardiac hypertrophy.
Myocardial hypertrophy, resulting from increased hemody-
namic load or hormonal stimuli, tends to progress to cardiac
dysfunction and heart failure (1). In vitro (2) and in vivo evi-
dence fromanimal (3–5) and clinical studies (6–8), as well as ex
vivo evidence (from autopsy and biopsy samples of cardiac
muscle from diabetic patients with congestive heart failure) (9),
all indicate a link between insulin resistance (and the associated
hyperinsulinemia), and cardiac hypertrophy/heart failure.
However the targets of insulin in hypertrophy signaling remain
poorly defined.
Recent studies have suggested that the transcription factors
myocardin and serum response factor (SRF)2 may be potential
regulators of cardiac gene expression in response to hypertro-
phy signals (10). SRF, an MCM1, Agamous Deficiens, SRF
(MADS)-box transcription factor related to myocyte enhancer
factor-2c (MEFc2), interacts with myocardin to bind the DNA
consensus sequence CCA/T6GG (CArG box), and is involved
in the activation of several cardiac genes, including -actinin
and myosin heavy chain (MHC) (11, 12). Myocardin physically
interacts with, and is a target for, ubiquitin-mediated proteoly-
sis via the chaperone-associated ubiquitin (Ub) E3 ligase C ter-
minus of Heat shock Protein 70-interacting protein (CHIP),
which functions in protein quality control and plays important
roles in cell proliferation and apoptosis (13, 14).
There is a growing consensus that diabetes-induced activa-
tion of nuclear factor-B (NF-B) contributes to the pro-in-
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flammatory diabetic milieu, including myocardial inflamma-
tion, occurring in this condition (15–17). Tumor necrosis
factor (TNF)-, which is found at high levels in patients with
insulin resistance, activates NF-B (18). In turn, NF-B inter-
acts with other transcription factors, including SRF (19), in
inducing inflammation, immune responses, and cellular prolif-
eration (20, 21). In patients with insulin resistance, insulin and
TNF- may synergize in both pro-inflammatory and cardiac
hypertrophy signaling. Anumber of clinical studies have indeed
indicated a link between NF-B activation, cardiac hypertro-
phy, and cardiovascular disease (22, 23), including diabetic car-
diomyopathy (see (24) for a comprehensive review). Despite
this body of evidence, the mechanisms and targets by which
insulin signals inflammation and hypertrophy remain poorly
understood.
Aims of this study were therefore to elucidate the mecha-
nisms of cardiac hypertrophy in insulin resistance, to test
whether high insulin levels affect TNF--induced activation of
NF-B, and to examine the relationship between myocardin,
SRF, and NF-B in the regulation of the hypertrophy signaling
in cardiac myoblasts.
EXPERIMENTAL PROCEDURES
Human Recombinant Insulin—TNF-, pyrrolidine dithio-
carbamate (PDTC), andMTG132were purchased from Sigma-
Aldrich. The Akt/phosphatidyl inositol (PI3)-kinase inhibitor
LY294002 was from Calbiochem, La Jolla, CA.
Animal Care—The study population comprised wild-type
C57BL/6 (body weight: 22 4 g, n 3 male and n 3 female),
and Leprdb (db/db) mice on a C57BL/6 background (homozy-
gotes for a mutation in the leptin receptor gene leading to the
loss of a functional leptin receptor) (25) (body weight: 76 5 g,
n 3 male and n 3 female), of comparable age (12 months),
purchased from The Jackson Laboratories, Bar Harbor, ME.
Physiological and biochemical parameters in db/db and
C57BL/6 mice have been previously reported by us (26). Db/db
mice on a C57BL/6J background develop hyperphagia, obesity,
and insulin resistance, with severe depletion of the insulin-pro-
ducing beta-cells of pancreatic islets (25). Their diabetic phe-
notype, however, is less severe compared with db/db mice on a
KsJ background (27). The latter, despite being more severely
insulin resistant are less hyperglycemic compared with db/db
mice on aC57BL/6J background (27). Db/dbmice onC57BL/6J
background develop higher plasma fatty acids levels compared
with db/dbmice on a KsJ background. All animals were specific
pathogen-free and kept in a temperature-controlled environ-
ment in a ventilated rack with a 12 h:12 h light:dark cycle. Food
andwater were given ad libitum. All procedures were approved
by the Institutional Ethics Committee for Animal Research of
theUniversity of TexasHealth ScienceCenter atHouston). The
investigations conformed to the Principles of Laboratory Ani-
mal Care formulated by the National Society for Medical
Research and the Guide for the Care and Use of Laboratory
Animals published by the United States National Institutes of
Health.
Cell Culture and Insulin Treatments—Cardiac myoblasts
(CMs)were isolated from canine embryonic hearts by collagen-
ase digestion, as previously reported (28). Cells were cultured in
Iscove’s medium supplemented with 15% embryonic stem cell-
qualified fetal bovine serum (FBS) (Stem Cell Technologies,
Vancouver, British Columbia, Canada), 2 mM glutamine, 100
IU/ml penicillin, and 0.1 mg/ml streptomycin. At subconflu-
ence, passage 3 CMs were serum-starved for 12 h before being
further incubatedwith insulin (108 to 107mol/liter) for up to
24 h with or without TNF- (10 ng/ml) or LY294002 (50mol/
liter). Cell viability after treatments was assessed by evaluating
several parameters, including cell morphology and size at
phase-contrastmicroscopy, Trypan Blue exclusion, determina-
tion of total proteins.
Cloning of CHIP Expression Plasmids and Transient
Transfections—Transfections were performed on subconfluent
canine cardiac myoblasts by using Lipofectamine (Invitrogen,
Grand Island, NY), according to the manufacturer’s specifica-
tions. Transfected cells were selected with 400 g/ml G418
(Sigma-Aldrich) for 15 days. Neomycin-resistant clones were
used for further experiments. pcDNA3.1 myc-His expression
plasmid (Invitrogen, Catalogue number V855-20) encoding
cDNA for human CHIP (GenBankTM accession number
NM_005861.2) and pcDNA3.1 myc-His empty vector were a
gift from Cam Patterson (among the co-authors of this study)
(data not shown). The construct was confirmed by HindIII and
XbaI restriction enzyme digest analysis (data not shown).
Western analysis was used to analyze protein expression of
CHIP in canine cardiac myoblasts by means of anti-CHIP anti-
body and anti-His6 antibody (Invitrogen).
Silencing of Myocardin, NF-B, and CHIP by siRNA—A pool
of three different small interferingRNAs (siRNAs) oligonucleo-
tides against CHIP or myocardin or NF-B, or scrambled neg-
ative control siRNAs, were obtained fromAmbion. Briefly, 2
105 cells/well were plated in 6-well plates in low-serummedium
without antibiotics (OptiMem, Invitrogen). Cells were incu-
bated with 6 l of siRNA transfection reagent containing 15
nmol/liter of one of the following: a mixture of 3 different
siRNAs against CHIP, or against myocardin, or against NF-B
or scrambled siRNA (negative control). Transfection medium
was added up to a total volume of 800 l. After 24 h, fresh
medium was added, and cells were incubated for an additional
16 h. At the end of incubations, total RNA was harvested for
quantitative real-time polymerase chain reaction (qRT-PCR) or
protein extracted for Western blotting and electrophoretic
mobility shift assay (EMSA), as described below.
RNA Analysis of -MHC by qRT-PCR—Total RNA was iso-
lated by using a Qiagen RNA isolation kit and used directly for
qRT-PCR with the SuperScript™ III Platinum SYBR Green
One-Step qRT-PCR Kit (Invitrogen) according to the manufa-
cturer’s protocol. Primers for qRT-PCRwere designed by using
the OligoPerfectTM Designer software (Invitrogen). All qRT-
PCR reactions were performed in triplicate by using aMyiQTM
single-color RT-PCR detection system (Bio-Rad). A melting
curve was generated at the end of every run to ensure product
uniformity. Relative expression values were obtained by nor-
malizing CT values of the tested genes in comparison with CT
values of the RNA 18 S using the CT method.
Immunoprecipitation, in Vitro Ubiquitination, and Im
munoblotting—Total or nuclear proteins were extracted as
described (29). Proteins were separated under reducing condi-
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tions and electroblotted onto polyvinylidene fluoride mem-
branes (Immobilon-P;Millipore, Billerica,MA). After blocking,
the membranes were incubated overnight at 4 °C with the fol-
lowing primary antibodies: total or phosphorylated insulin
receptor substrate (IRS-1) (Santa Cruz Biotechnology), myo-
cardin (R&D Systems, Minneapolis, MN), MEF2c (Santa Cruz
Biotechnology), CHIP (Santa Cruz Biotechnology), ubiquitin
(Santa Cruz Biotechnology), lamin-B (Santa Cruz Biotechnol-
ogy), atrial natriuretic peptide (ANP, Santa Cruz Biotechnol-
ogy), -MHC (Santa Cruz Biotechnology), Akt1 isoform and
total pAkt (Cell Signaling, Danvers, MA), and -actin (Sigma).
Blots were developed by using a SuperSignalWest Pico Chemi-
luminescent Substrate Kit (Pierce). The intensity of each
immunoreactive protein band was measured by densitometry.
For immunoprecipitation, the nuclear lysates were mixed with
a primary antibody against myocardin (R&D), and immuno-
complexes were precipitated with protein-G beads (Sigma).
Immunoprecipitates were then eluted, concentrated, and sub-
jected to immunoblotting. For in vitro ubiquitination reactions,
immunoprecipitates were incubated in 50 l of control buffer
(phosphate-buffered saline) or Ub reaction buffer (30 mM
Hepes, pH 7.5, 5 mM MgCl2, 2 mM ATP, 0.2 mM DTT, 10 mM
sodium citrate, 10 mM creatine phosphate, and 0.2 g/ml crea-
tine kinase), 30 nM of E1 enzyme (purchased from Boston
Biochem), 0.5 M of E2 enzyme (Boston Biochem), and 10 M
ubiquitin (Boston Biochem). After incubation at 37 °C for 4 h,
reaction products were analyzed by immunoblotting with the
indicated antibodies.
Immunofluorescence Microscopy and Cell Size Measure-
ment—Cells grown in eight-well glass chamber slides (Lab-Tek,
Pieve D’Alpago, Italy) were fixed with 4% paraformaldehyde,
permeabilized, and then blocked in phosphate-buffered saline
(PBS) containing 1% bovine serum albumin for 30 min. Cells
were incubated in this solution with a primary antibody against
-sarcomeric actinin (SigmaAldrich) or-MHC for 1 h at 4 °C.
After being incubated and washed in PBS, the slides were
incubated with a Texas Red-conjugated anti-rabbit second-
ary antibody (Invitrogen). Non-immune IgG (Sigma-Al-
drich) was used as the isotype control. Slides were washed
and mounted with a solution containing 4,6-diamidino-2-
phenylindole (VectaShield; Vector Laboratories, Burlin-
game, CA) and viewed through a fluorescence microscope.
The cell surface area of -sarcomeric actinin-stained cells or
unstained cells was measured with the computer-assisted
planimetry (N.I.H. Image J) software. The size of adherent
cells was assessed by examining 8 different high-power fields
(0.09 mm2/field), randomly located at half-radius distance
from the center of the monolayers.
Electrophoretic Mobility Shift Assays (EMSA)—Nuclear pro-
teins were extracted as described (29, 30). Double-stranded
serum response element (SRE) consensus oligonucleotides (5-
GGATGTCCATATTAGGACATCT-3), SRE mutant oligo-
nucleotides (5-GGATGTCCATATTATTACATCT-3) (both
from Santa Cruz Biotechnology) and NF-B oligonucleotides
(5-AGT TGA GGG GAC TTT CCC AGG C-3 and 5-CCT
GGG AAA GTC CCC TCA ACT-3) (Promega) were labeled
with [-32P]ATP. Binding reactions containing 10 g of crude
nuclear extract were performed by using an EMSA core system
(Promega) according to the manufacturer’s protocol. For
supershift assays, goat monoclonal anti-myocardin or anti-p65
antibodies (Santa Cruz Biotechnology) were used.
Statistical Analysis—Two-group comparisons were per-
formed with the Student’s t test for unpaired values. Multiple-
group comparisons were performed with the analysis of vari-
ance (ANOVA). A p value0.05 was considered significant.
RESULTS
Myocardin Participates in Mediating Insulin Hypertrophy
Signal in Canine Cardiac Myoblasts—Although insulin is
known to be able to induce cardiomyocyte hypertrophy (2, 4),
and although myocardin is known to be able to mediate hyper-
trophy signals (31), whether myocardin conveys the hyper-
trophic signal of insulin is unknown. We therefore explored
whether myocardin is necessary for insulin to induce hypertro-
phy, and analyzedmyocardin levels in response to insulin treat-
ment. Treatment of cells with pathophysiologically relevant
concentrations of insulin (108–107 mol/liter) increased
myocardin levels and activated insulin signaling, as shown by
increased levels of phosphorylated IRS-1 (Fig. 1, panel A). The
Akt-mediated insulin signaling inhibitor LY-294002 attenuated
myocardin levels upon insulin treatment. BecauseMEF2c, a key
regulator of early cardiomyogenesis, is known to regulate tran-
scriptional expression of myocardin through its enhancer (32),
we also analyzedMEF2c levels in response to insulin treatment.
Treatment of cells with insulin (108–107 mol/liter) led to an
increase in MEF2c levels (Fig. 1, panels A and B), which was
attenuated by LY-294002 (Fig. 1, panels A and B). These data
suggest that insulin inducesmyocardin and its activatorMEF2c
in canine cardiac myoblasts.
To determine if myocardin plays a functional role in insu-
lin-induced hypertrophy, we tested whether the inhibition
of myocardin is able to influence hypertrophy. We used
siRNA-mediated targeted disruption of myocardin gene
expression to specifically block myocardin. Transfection
efficiency with myocardin siRNA was 	90%. Myocardin
siRNA did not affect cell proliferation (data not shown).
Treatment with myocardin siRNA, but not a scrambled
siRNA sequence, resulted in a substantial (90%) reduction of
myocardin protein expression (Fig. 1D). Treatment of canine
cardiacmyoblasts with insulin (107 mol/liter) resulted in an
increase in the hypertrophic marker -MHC (Fig. 1C).West-
ern analysis of ANP did not show any re-expression of this
fetal gene in canine cardiac myoblasts at baseline and after
insulin treatment (data not shown). Myocardin siRNA atten-
uated insulin-induced increase in -MHC expression (Fig.
1C). Insulin treatment also led to an increase in cell size of
canine cardiac myoblasts, which was inhibited by siRNAs
against myocardin (Fig. 1E). Thus, myocardin likely partici-
pates in conveying the hypertrophy signals of insulin.
Insulin Enhances SRF-SRE Binding—SRF is a nuclear tran-
scription factor that binds to the SREofDNAsequences located
in the promoter of genes critical for cardiovascular myogenesis
and cardiac hypertrophy (25, 33, 34). To determine if myocar-
din, an important co-activator of SRF, can interact with SRF in
response to insulin treatment by binding to SREs located in the
promoter of such genes, we performed EMSA with nuclear
Insulin, NF-B, andMyocardin Signaling in CardiacMyoblasts
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extracts from canine cardiac myoblasts treated with insulin
(108-107 mol/liter) and incubated with a radiolabeled dou-
ble-stranded DNA SRE probe ([32P]SRE). SRF-SRE activity, a
preliminary requirement for myogenesis, was thus detected
(Fig. 2, panels A and B). In nuclear protein extracts from cells
treated with insulin, a strong binding activity was indicated by
the appearance of shifted bands. The specificity of the SRF-32P-
SRE bindingwas confirmedwith the use ofmutant probes or by
competition with non-radioactive or mutated probes, which
led to the disappearance of shifted bands.Moreover, addition of
a specific antibody against myocardin resulted in super-shifted
bands (Fig. 2, panels A and B), indicating that myocardin was
present in the protein-SRE probe complexes. Quantitative
analysis of the shifted bands confirmed that insulin treatment
enhanced SRF binding activity. The Akt inhibitor LY-294002
attenuated the SRF-SRE activity upon insulin treatment. To
further confirm that myocardin plays a functional role in insu-
lin-induced SRF-SRE activity, we also tested whether the inhi-
bition of myocardin can influence insulin-induced SRF-SRE
activity. Indeed, myocardin siRNA could substantially attenu-
ate the SRF-SREbinding induced by insulin (Fig. 2,panels C and
D). Thus, insulin treatment increases the binding of SRF to the
SRE in canine cardiac myoblasts through the activation of
myocardin.
Insulin Increases Myocardin Levels and Activity through
CHIP—Insulin stimulates the chaperone-associated ubiquitin
(Ub) ligase CHIP (35). In turn, CHIP regulates the stability of
myocardin protein by interacting with and promoting ubiqui-
tin-mediated degradation of myocardin by the proteasome
complex (14). We therefore first tested whether CHIP is regu-
lated by insulin. Insulin treatment of canine cardiac myoblasts
led to a significant reduction in CHIP protein levels (Fig. 3,
panels A and B). We then carried out experiments to under-
stand the functional role of CHIP in hypertrophy, and the rela-
tionship betweenCHIP andmyocardin in the hypertrophic cas-
cade of insulin. We tested whether CHIP can regulate
myocardin activity by SRF-SRE binding upon treatment with
insulin, and whether it can influence the expression of the
FIGURE 1.Myocardin induction by insulin and myocardin requirement for insulin-mediated induction of myosin heavy chain-. A and B, myocardin
(MYOCD) up-regulation in response to insulin treatment. Canine cardiacmyoblastswere starvedbygrowth factorwithdrawal and serum reduction (decreased
to 2%) for 12 h, followed by stimulation with pathophysiologically relevant concentrations of insulin (108-107 mol/liter) for 24 h with or without the Akt
inhibitor LY294002 (5 107 mol/liter), which was added to the medium 30 min prior to insulin. Following treatments, the expression of myocardin, MEF2c,
and p-IRS-1 were detected by immunoblotting. Blots shown are representative of three independent experiments. The results of scanning densitometry (n
3 independent experiments) are expressed as arbitrary units in panel B. Columns andbars represent themean S.D. (**, p 0.01, versusuntreated cells; ˆˆ, p
0.01 versus insulin-treated cells). C, myocardin requirement for insulin-mediated induction of the hypertrophymarker -MHC. Canine cardiac myoblasts were
transfectedwith apool of threedifferent siRNAsagainstmyocardinor a scrambled (scr) siRNA (negative control) and treatedwith insulin (107mol/liter) for 6h.
Total RNA was analyzed by real-time quantitative-PCR with primer sets specific for -MHC. Data (means  S.D. of three independent experiments) are
presented as relativemRNAexpression (normalized to RNA18 S). *, p 0.05 versusuntreated cells; #, p 0.05 versus insulin treated cells.D, levels ofmyocardin
in total protein extracts isolated from canine cardiac myoblasts transfected with a pool of three different siRNAs against myocardin or scrambled siRNA
(negative control). Blots are representative of three independent experiments. E, insulin treatment (108mol/liter) led to cell size increase, whichwas blocked
by myocardin-siRNA. Representative photos show cell size of canine cardiac myoblasts. Canine cardiac myoblasts were treated as described for A–C. After
treatment, cells were permeabilized and fixed for the staining with -sarcomeric actinin (-sarc). Nuclei were stained with 4,6-diamidino-2-phenylindole.
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hypertrophymarker-MHC. EMSA experiments andWestern
analyses were performed in canine cardiac myoblasts at base-
line and after treatment with insulin (108-107 mol/liter)
in the presence or absence of CHIP siRNA and CHIP
overexpression.
Overexpression of CHIP in canine cardiac myoblasts was
achieved by stable cDNA transfection (data not shown). Trans-
fection efficiency with CHIP siRNA or CHIP-overexpressing
plasmid was 	90%. Treatment with CHIP siRNA, but not a
scrambled siRNA sequence, resulted in a significant (50%)
reduction of CHIP protein expression. CHIP siRNA substan-
tially increased the SRF-SRE binding induced by insulin (Fig. 3,
panel D, lanes 5 and 6, and panel C), while the proteasome
inhibitor MG132 (10 nmol/liter) (Fig. 3, panel D, lanes 4 and 7,
and panel C) and CHIP overexpression (Fig. 3, panel E, lanes 11
and 12, and panel F) decreased the SRF-SREbinding induced by
insulin. Furthermore, CHIP siRNA, but not a scrambled siRNA
sequence, resulted in an increase in the hypertrophy marker
-MHC (Fig. 4, A and C), while it potentiated the insulin-in-
duced expression of -MHC (Fig. 4,A and C). On the contrary,
CHIP overexpression (CHIP-TR), but not an empty vector,
resulted in a decrease in -MHC (Fig. 4B), while it reverted the
insulin-induced expression of -MHC (Fig. 4B). Thus, CHIP is
a target of insulin and plays a role as an anti-hypertrophymedi-
ator; and insulin increasesmyocardin levels and SRF-SRE bind-
ing activity in a CHIP-dependent manner.
Finally, we sought to ascertain whether the effect of CHIP on
myocardin protein levels occurs through proteasome degrada-
FIGURE 2.Myocardin requirement for insulin-mediated SRF-SRE binding. A, EMSA assessing the SRF-SRE binding activity in canine cardiac myoblasts in
response to insulin. Canine cardiac myoblasts were starved by growth factor withdrawal and serum reduction (decreased to 2%) for 12 h followed by
stimulation with pathophysiologically relevant concentrations of insulin (108-107 mol/liter) for 2 h with or without the Akt inhibitor LY294002 (5 107
mol/liter), which was added to the medium 30 min prior to insulin. Following treatments, nuclear extracts (10 g) were incubated with or without 32P-end-
labeled SRE oligonucleotides. The specificity of the myocardin-SRF-SRE complex formation was determined by competition with either unlabeled oligonu-
cleotide or mutated, labeled SRE oligonucleotides and by the presence of a supershift after the addition of an anti-MYOCD antibody. Here shown is a
representative EMSA from three independent experiments are shown. B, densitometry of protein-DNA complexes in three different EMSAexperiments. **,p
0.01 versus untreated cells; *, p 0.05 versus insulin treated cells. C, canine cardiac myoblasts were transfected with a pool of three different myocardin siRNA
oligonucleotides or a scrambled (scr) siRNA (negative control) followed by treatment with insulin (108) for 2 h. At the end of the treatment period, nuclear
extracts (10 g) were incubated with or without 32P-end-labeled SRE oligonucleotides. Specificity of the myocardin-SRF-SRE complex formation was deter-
mined by the presence of a supershift after the addition of an anti-myocardin antibody. Here shown is a representative EMSA from three independent
experiments. D, densitometry of protein-DNA complexes in three different EMSA experiments. **, p 0.01 versus untreated cells; ˆˆ, p 0.01 versus insulin-
treated cells.
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tion upon insulin treatment (Fig. 4, panels D and E). We there-
fore analyzed ubiquitination of myocardin by immunoblotting
with an anti-Ub antibody, and looked for high-molecular
weight bands. As shown in Fig. 4, panel E, ubiquitination of
myocardin was substantially decreased with insulin treatment.
CHIP siRNA could further decrease myocardin ubiquitination
upon insulin treatment (Fig. 4, panel E).
TNF-Potentiates Insulin-induced SRF-SREBindingActivity
and Expression of the Hypertrophy Marker -MHC—TNF- is
a potent mediator of inflammation and insulin resistance,
and is known to synergize with other inflammatory stimuli in
increasing intracellular oxidative stress (36). TNF- acti-
vates the redox-sensitive transcription factor NF-B, which
interacts with other families of pro-myogenic transcription
factors, including SRF, to induce cardiac hypertrophy (19).
In previous work we have shown that insulin synergizes with
TNF- to induce NF-B activation in endothelial cells (37–
40). Here we tested whether insulin could induce NF-B
expression in canine cardiac myoblasts exposed to TNF-.
Insulin treatment indeed led to significant activation of
NF-B andmarkedly increased TNF--induced activation of
NF-B (Fig. 5, panel A). The specificity of the NF-B DNA-
protein complex was verified by successful competition with
an unlabeled (cold) NF-B oligonucleotide and by the lack of
any binding with a mutated oligonucleotide (not shown). In
addition, there was no significant specific binding with the
unlabeled (cold) oligonucleotide (Fig. 5, panel A, lane 13),
nor was there any specific binding when either nuclear pro-
tein extracts or the oligonucleotide probe were omitted (not
shown). Nuclear protein extracts from unstimulated myo-
FIGURE3.CHIP-dependent insulin inductionofmyocardin levels andof SRF-SREbindingactivity.A, insulin-mediated reductionof chaperone-associated
ubiquitin (Ub) E3 ligase CHIP. Canine cardiacmyoblasts were starved by growth factor withdrawal and serum reduction (decreased to 2%) for 12 h followed by
stimulation with pathophysiologically relevant concentrations of insulin (108–107 mol/liter) for 24 h with or without the Akt inhibitor LY294002 (5 107
mol/liter), which was added to the medium 30 min prior to insulin. Following treatments, CHIP and MYOCD expressions were detected by immunoblotting.
Here shown is a blot representative of three independent experiments. B, results of scanning densitometry (n 3 independent experiments) expressed as
arbitrary optical density units. Columns andbars represent themean S.D. (**,p0.01 versusuntreated cells; ˆˆ,p0.01 versus insulin-treated cells; ˆ,p0.05
versus insulin-treated cells). C, densitometry of protein-DNA complexes in three different EMSA experiments represented in panel D. **, p  0.01 versus
untreated cells; ˆˆ, p  0.01 versus insulin-treated cells; ˆ, p  0.05 versus insulin treated cells. D–F, CHIP-dependent, insulin-mediated increase of SRF-SRE
binding activity. D, canine cardiac myoblasts were transfected with a pool of three different CHIP siRNA oligonucleotides or a scrambled (scr) siRNA (negative
control), and treated with insulin (108–107 mol/liter) for 2 h. A parallel set of cardiac myoblasts was pre-treated with the proteasome inhibitor MG132 (10
mol/liter) for 6 h prior to the addition of insulin. E, canine cardiac myoblasts were mock-transfected (mock-TR, negative control) or transfected with CHIP
(CHIP-TR), or transfected with a pool of three different CHIP siRNA oligonucleotides, then treated with 108 mol/liter insulin for 2 h. After treatments, nuclear
extracts (10 g) were incubated with or without 32P-end-labeled SRE oligonucleotides. Specificity of the SRF-SRE complex formation was determined by
showing competitionwith anunlabeled oligonucleotide. EMSA representatives of three independent experiments are shown. F, densitometry of protein-DNA
complexes in three different EMSA experiments represented in panel E. **, p 0.01 versus untreated cells; ˆˆ, p 0.01 versus insulin-treated cells.
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blasts also failed to show any specific binding (Fig. 5, panel A,
lanes 11–12).
We next examined the effect of the proteasome inhibitor
MG132 (10 nmol/liter), which inhibits NF-B formation and
degradation of its inhibitor I-B, on insulin-induced NF-B
activation in the presence or absence of TNF-. In the absence
of any cytotoxicity, treatment of canine cardiac myoblasts with
MG132 significantly decreased the induction ofNF-B by insu-
lin with or without TNF- (Fig. 5, panel A, lanes 3–6).We next
carried out experiments to understand the relationship
between TNF- and NF-B in the insulin-mediated hypertro-
phy signaling cascade. TNF- treatment led to a significant
increase in SRF-SRE binding and markedly increased insulin-
induced activation of SRE, which was further potentiated by
CHIP siRNA (Fig. 5, panel A, lanes 1–4). The antioxidant pyr-
rolidine dithiocarbamate (PDTC) has been shown in previous
work to inhibit NF-B activation (41). In our study, PDTC sub-
stantially reduced the SRF-SRE binding induced by insulin and
TNF- (Fig. 5, panel B, lane 5). In parallel, TNF- treatment led
to a significant induction of MHC- expression (Fig. 6, panels
A, B, and C) and markedly potentiated the insulin-induced
expression of this hypertrophy marker (Fig. 6, panels A, D, and
E). NF-B-directed siRNA significantly decreased the induc-
tion of MHC- expression by insulin with or without TNF-.
These effects were further enhanced by the simultaneous
silencing of myocardin and NF-B, indicating a cooperation
between these transcription factors in regulating MHC-
expression (Fig. 6). Taken together, these results demonstrate
that bothNF-B andmyocardin play a key role inmediating the
activation of the pro-myogenic program in canine cardiacmyo-
blasts exposed to insulin and TNF-.
Hearts of Obese db/db Mice Feature Selective Insulin Resis-
tance Signaling—We then expanded the in vitro studies inves-
tigating the diabetic mouse heart at 12 months. As expected,
db/dbmice at 12 months of age fed normal chow featured sig-
nificant body weight gain, with marked elevation of blood lip-
ids, insulin, and glucose. The db/db mice were much heavier
than non-diabetic C57BL/6J control mice of the same age (26).
There was a modestly, but significantly (p 0.05) higher heart
weight, as well as heart weight/body weight ratio in db/db com-
pared with C57BL/6Jmice. There were also significantly higher
blood levels of glucose and insulin, total cholesterol, LDL and
VLDL cholesterol, and triglycerides in db/db mice compared
with non-diabetic control mice (p  0.01, p  0.01, p  0.01,
p 0.05, and p 0.01, respectively, n 3 in each group). Thus,
compared with control C57mice, db/dbmice developed severe
obesity, hyperlipidemia, and hyperglycemia, as also previously
reports by us (26).
Here we evaluated protein levels of the insulin receptor (IR)
in the hearts of C57BL/6 and db/dbmice semi-quantitatively by
immunoblotting with an anti-IR antibody. Fig. 7A, panel a
shows an immunoblot with a broad brand corresponding to a
FIGURE 4. Insulin down-regulation of ubiquitinated CHIP and modulation of myosin heavy chain- in response to overexpression and silencing of
CHIP. A, -MHC induction in response to CHIP-siRNAs and/or insulin. Canine cardiac myoblasts were transfected with a pool of three different CHIP siRNAs
oligonucleotides or a scrambled (scr) siRNA (negative control), and treatedwith insulin (108–107mol/liter) for 24 h. B,-MHC repression in response to CHIP
overexpression. Canine cardiac myoblasts were either mock-transfected (mock-TR, negative control) or transfected with CHIP (CHIP-TR), then treated with
108 mol/liter insulin (108-107 mol/liter) for 24 h. Following treatments, the expression of -MHC was detected by immunoblotting. Blots shown are
representative of three independent experiments. C, results of scanning densitometry (n  3 independent experiments) expressed as a ratio of -MHC to
-actin in three different immunoblots represented in panels A and B. Columns and bars represent themean S.D. (**, p 0.01, versus untreated cells; ˆˆ, p
0.01 versus insulin-treated cells). D–E, insulin-mediated decrease of CHIP ubiquitination. Canine cardiac myoblasts were transfected with a pool of three
different CHIP siRNA oligonucleotides or a scrambled siRNA (negative control), and then treated with insulin (108 mol/liter) for 24 h. Proteins were immuno-
precipitated with an anti-myocardin antibody and subjected to ubiquitination reactions (panel D, lane 6 and panel E). Panel D, lanes 1–5 shows control
experiments with immunoprecipitates incubated in 50 l of control buffer. Reactions were resolved by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis, followed by immunoblotting with anti-Ub antibody (panels D and E). Here shown is a blot representative of three independent experiments.
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protein migrating between 95 and 125 kDa, consistent with the
 and  subunits of the IR, indicating no differences between
the two groups of mice. Fig. 7A, panel b shows the phosphoser-
ine proteins in hearts of C57BL/6 and db/db mice detected by
an antibody against phosphorylated serine 307, revealing a
closely spaced doublet with molecular mass between 170 and
185 kDa, consistent with phosphorylation of IRS-1 at serine
307. IRS-1 has numerous phosphorylation sites, consisting of
both tyrosine and serine residues, and (depending on the level
of hyperphosphorylation) has different electrophoretic mobili-
ties (42, 43). Tyrosine residues are required for the activation of
IRS proteins, whereas serine residues are involved in a negative
feedback loop, functioning to de-activate IRS proteins (43, 44).
While similar tissue levels of total IRS-1 were found in hearts
from the two strains of animals studied (not shown), a nearly
2-fold increase of serine 307-phosphorylated IRS-1 was
observed in db/db comparedwith C57BL/6mice (p 0.01, n
3) (Fig. 7A, panel b). The activity of Akt was evaluated by inves-
tigating the phosphorylation of serine 473, which represents
the final step ofAkt activation togetherwith phosphorylation of
threonine 308 (45). As shown in Fig. 7A, panel c, there was a
marked decrease in the expression of phospho-Akt protein in
db/db compared with C57BL/6 mice. On the contrary, there
was an increase of Akt1 isoform expression in the db/db mice
(Fig. 7A, panel c). Together, these results indicate that a defect
of the PI3-kinase/Akt-dependent insulin signaling in obese
db/dbmice is associated with (and likely depends on) a pertur-
bation in the signaling pathway downstream of the IR, leading
to a decrease in the metabolic insulin signaling pathway. In
contrast to the activation pattern of PI3K, the pattern of mito-
gen-activated protein kinase (MAPK) phosphorylation of
extracellular signal-regulated kinase (ERK)44 and p38mirrored
that of serine 307 phosphorylation-dependent IRS-1 activation
in db/db mice. As shown in Fig. 7A, panels d and e, ERK44
phosphorylation was significantly greater (by 6-fold, p 0.001)
in db/db mice than in control mice. Similar to ERK44, p38
FIGURE 5. Co-Activation of NF-B and myocardin/SRF in response to insulin. A, insulin induction of NF-B in myoblasts exposed to TNF-. EMSA was
performed by mixing the 32P-oligonucleotide containing the NF-B consensus sequence with nuclear proteins from canine cardiac myoblasts treated with
insulin (108 mol/liter) for 16 h prior to TNF- stimulation (10 ng/ml, added to cardiac myoblasts during the last 15 min of insulin treatment). A parallel set of
cardiac myoblasts was pre-treated with the proteasome inhibitor MG132 (10 nmol/liter) for 6 h prior to insulin addition. The results of an EMSA with nuclear
protein extracts from cardiac myoblasts treated with insulin with or without TNF- (10 ng/ml) or TNF- alone are shown. Specificity of the SRF-SRE complex
formation was determined by competition with an unlabeled oligonucleotide. Results shown here are representative of three independent experiments. B,
role of NF-B in mediating the SRF-SRE binding activity in cardiac myoblasts treated with insulin and TNF-. Canine cardiac myoblasts were transfected with
a pool of three different CHIP siRNAs or a scrambled (scr) siRNA (negative control) and treated with insulin (108 mol/liter) 16 h prior to TNF- stimulation (10
ng/ml, added to cardiac myoblasts during the last 15 min of insulin treatment). A parallel set of cardiac myoblasts was pre-treated with the NF-B inhibitor
PDTC for 6 h prior to insulin addition. Following treatments, nuclear extracts (10 g) were incubated with or without 32P-end-labeled SRE oligonucleotides.
Specificity of the SRF-SRE complex formation was determined by competition with a cold oligonucleotide and mutated labeled SRE oligonucleotides. Here
shown is an EMSA representative of three independent experiments.
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phosphorylation also increased in db/dbmice (by 2.5-fold, p
0.01) compared with wild-type mice (Fig. 7A, panel e).
Hearts of Obese db/db Mice Show Evidence for Increased
Hypertrophy Signaling—Analysis of cardiac tissues in db/db
mice showed significant up-regulation of myocardin as well as
MEF2c at the protein level (Fig. 7B, panels a and c). This
increased expression was evident after 4 months and was sus-
tained after 12 months of diabetes, and was associated with
decreased expression of CHIP (Fig. 7B, panel d). Conversely,
SRF levels were similar in db/db mice compared with age and
sex-matched C57BL/6J mice (Fig. 7B, panel b). In agreement
with our previous report (26), diabetic animals also showed
increased heart weight (0.4 0.05 g versus 0.1 0.03 g, n 3,
p 0.05 db/dbmice versusC57mice) and heart weight to body
weight ratio (HW/BW ratio: 0.005 0.05 versus 0.004 0.00,
n  3, p  0.05 dbd/db mice versus C57 mice). To determine
SRF activity, gel shift assay with 32P end-labeled SRE oligonu-
cleotides was conducted using the nuclear proteins isolated
from snap-frozen hearts. As shown in Fig. 8, panels A and B,
SRF binding activities were much stronger in the nuclear
extracts from age- and sex-matched hearts of db/dbmice than
those from wild-type controls, indicating their potential for
myogenesis. The specificity of the SRF-DNA protein complex
formation was verified by competition with cold oligonucleo-
tides. The binding activity with the radioactive oligonucleotide
probe was abolished in the absence of protein extracts (Fig. 8,
panel A, lane 7), indicating the dependence of the shifted radio-
active bands on nuclear protein factor binding. To determine if
myocardin, an important co-activator of SRF, can interact with
SRF in the hearts of db/db mice, supershift analyses were car-
ried out by adding anti-myocardin antibody (Fig. 8, panel A,
lanes 2 and 5). The antibody to MYOCD super-shifted a por-
tion of the complexes consisting of nuclear protein binding to
DNA, indicating that myocardin was present in the protein-
SRE probe complexes. Expression and activity of NF-B were
also analyzed in the hearts ofdb/db andC57mice. In agreement
FIGURE 6. The role ofNF-Bandmyocardin inmediatingmyosin heavy chain- expression in cardiacmyoblasts treatedwith insulin andTNF-. Panel
A, canine cardiac myoblasts were transfected with a pool of three different anti-myocardin siRNAs (MYOCD-siRNA) and/or anti-NF-B siRNAs or a scrambled
(scr) siRNA (negative control), and treated with insulin (108 mol/liter) with or without TNF- (10 ng/ml) for 24 h. Following treatments, cells were permeabi-
lized and fixed for the staining with an anti-myosin heavy chain (MHC)- antibody. Nuclei were stained with 4,6-diamidino-2-phenylindole. Representative
photos show cell size of canine cardiac myoblasts and expression of MHC-. Panels B and D, canine cardiac myoblasts were treated as described for A. After
treatment, the expression of MHC-was detected by immunoblotting. Blots shown here are representative of three independent experiments. The results of
scanning densitometry (n 3 independent experiments) are expressed as arbitrary units in panels C andD. Columns andbars represent themean S.D. Panel
C, **, p 0.01, versus untreated cells; ˆˆ, p 0.01 versus insulin-treated cells; °°, p 0.01 versus insulin
MYOCD-siRNA-treated cells or versus insulin
 NF-B
-siRNA-treated cells. Panel E, **, p 0.01, versus untreated cells or versus insulin
TNF--treated cells; ˆ, p 0.05 and ˆˆ, p 0.01 versus insulin
TNF--treated
cells; °, p 0.05 and °°, p 0.01 versus insulin
MYOCD-siRNA-treated cells or versus insulin
 NF-B -siRNA-treated cells.
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with our previous reports (26), NF-B binding activities were
much stronger in the nuclear extracts from age- and sex-
matched hearts of db/db mice than those from the wild-type
controls (Fig. 8, panels C and D).
DISCUSSION
A number of clinical studies have indicated a link between
insulin resistance/hyperinsulinemia, cardiac hypertrophy
and heart failure (6–8). Despite this body of evidence, the
downstream targets of insulin in the hypertrophy pathways
remain poorly understood. In the present study, we demon-
strate that myocardin is a modulator of such insulin-induced
hypertrophy.
We used insulin at concentrations that would bind and acti-
vate insulin receptors in endothelial cells (between 109 and
107 mol/liter) (46). Such concentrations, equivalent to 139–
13,900U/ml, range from pathophysiological to pharmacolog-
ical levels of insulinemia. Concentrations of 109 and 108
mol/liter are indeed attainable in fasting and post-prandial
states in individuals with insulin resistance (47), indicating that
our observations are applicable to in vivo settings where hyper-
insulinemia occurs, with all the caveats of extrapolating from in
vitro findings.
Myocardin exerts its pro-hypertrophic effect through SRF,
which binds to the SRE in the promoter region of genes that are
critical for myogenesis (48–50). Previous studies have shown
that insulin may initiate a hypertrophy cascade through Akt,
which in turn has been demonstrated to control the function of
hypertrophy regulators such as nuclear factor of activated T
cells (NFAT), GATA-4, and atrogin-1 (51). Our study shows
that the Akt inhibitor LY-294002 attenuates myocardin intra-
cellular levels upon insulin treatment. Thus, myocardin can be
a downstream target of the insulin/Akt axis in the induction of
hypertrophy.
How is myocardin activated in response to insulin signaling?
Based on our data, we suggest that at least twomechanisms are
involved: 1) myocardin transcripts and protein levels are
increased by insulin, which may account for the increase of
myocardin-dependent SRF-SRE binding and subsequent acti-
vation of themyogenic program; 2)myocardin activity, which is
independent of protein expression level, is induced by insulin
signaling, most likely through a post-translational change. Pre-
FIGURE 7. Insulin signaling andWestern analysis of cardiomyogenic genes in cardiac tissue of C57BL/6 and db/dbmice. Panel A, levels of IR subunits 
and , total Akt and the Akt1 isoform, and the phosphorylated isoforms of insulin receptor substrate (IRS)-1, extracellular signal-regulated kinase (ERK)44 and
p38 in total protein extracts isolated frommale (M) and female (F)db/dbmice comparedwith sex- andage-matchedC57BL/6 controlmice. Theblot shownhere
is representative of three independent experiments. Panel B, levels of MYOCD, SRF, MEF 2c, and the CHIP in total protein extracts isolated frommale (M) and
female (F) db/dbmice comparedwith sex- and age-matched C57BL/6 controlmice. Blots are representative of three independent experiments. Panel C, results
of scanning densitometry (n 3 mice per group) of experiments as of panel A are expressed as arbitrary units of optical density. Columns and bars represent
themean S.D. **, p 0.01, control versus non-diabetic control mice. Panel D, Results of scanning densitometry (n 3mice per each group) of experiments
as of panel B are expressed as arbitrary units of optical density. Columns and bars represent the mean S.D. **, p 0.01, control versus non-diabetic control
mice.
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vious studies have shown that CHIP promotes the ubiquitina-
tion of phosphorylated myocardin and its degradation by the
proteasome, thereby inhibiting myocardin-dependent myo-
genic gene expression (14). In this regard, our results show that
insulin down-regulates CHIP, which acts as a repressor ofmyo-
cardin expression through protein ubiquitination. Further-
more, previous work has shown that MEF2c regulates tran-
scriptional expression of myocardin through its enhancer (32).
Our data show that insulin increases levels of MEF2c, which
acts as an activator ofmyocardin expression by enhancingmyo-
cardin transcription. Thus, it appears that insulin and its down-
stream target Akt form an axis with myocardin and its regula-
tors, CHIP and MEF2c, participating in inducing cardiac
hypertrophy. Our data are therefore consistent with the
hypothesis that myocardin transcription and protein expres-
sion are increased by insulin, but do not allow us to determine if
post-translational modifications are additionally responsible
for insulin-dependent myocardin activation. This point
remains to be clarified.
In the db/db mouse model also used by us myocardin was
up-regulated without the activation of Akt signaling. This dis-
crepancy between the in vitro and in vivo settings might be due
to limitations in having used the db/dbmice as a model of type
2 diabetes, where the well-known inhibitory effect of hypergly-
cemia on Akt regulation (52) likely prevails over the effects of
hyperinsulinemia. Indeed, unlike other models of type 2 diabe-
tes (ob/ob mice, Zucker fatty rats), db/db mice are character-
ized by an earler and more intense development of hyperglyce-
mia relative to hyperinsulinemia (53). Alternatively, the
discrepancy may be due to the specific isoform of Akt chroni-
cally regulated in vivo by hyperinsulinemia. There is indeed
evidence of a divergent regulation of Akt1 and Akt2 in insulin
target tissues, where insulin exerts differential effects on these
isoforms in a tissue- and species-specific manner (54). Previous
studies have shown that chronic hyperinsulinemia may
increase myocardial Akt1 activation (55, 56). In the skeletal
muscle of obese Zucker rats, Akt2 is reduced, while Akt1 is
increased (54).
FIGURE 8. EMSA formyocardin-SRF-SRE andNF-B binding activities in cardiac tissue of C57BL/6 and db/dbmice. Panel A, SRF activity was determined
by EMSA, performed bymixing a 32P-labeled oligonucleotide encoding for the consensus sequence of serum response element (SRE)-binding promoter with
nuclear proteins from male (M) and female (F) db/db mouse hearts and sex/age-matched (12-month-old) control hearts (C57BL/6 mice), with n 3 mice per
group. Specificity of themyocardin-SRF-SRE complex formation was determined by the omission of nuclear proteins and by the presence of a supershift after
the addition of an anti-myocardin antibody. The electrophoretic run with nuclear protein extracts from C57BL/6 control hearts is shown in lanes 1–3. The
electrophoretic runwith nuclear protein extracts from db/dbmice is shown in lanes 4–6. The autoradiogram shown is representative of three separate gel shift
experiments for NF-B. Lane 7 shows the electrophoretic run by omitting protein extracts. Panel B, scanning densitometry (n 3mice per each group) of the
EMSAgels, expressed as arbitrary units of optical density. Columns and bars represent themean S.D. °°, p 0.01, control versus diabeticmice. Panel C, NF-B
activity was determined by EMSA, performed by mixing a 32P-labeled oligonucleotide encoding for the consensus sequence of the NF-B-binding promoter
with nuclear proteins from the hearts ofmale (M) and female (F) db/dbmice and sex- and age-matched C57BL/6 control mice (3mice per group). Specificity of
NF-Bbinding activitywas evaluatedby cold oligonucleotide analysis, the omissionof nuclear proteins andby theoccurrence of a supershift after the addition
of an anti-p65 antibody. The electrophoretic run with nuclear protein extracts from db/db mice is shown in lanes 8–11. The electrophoretic run with nuclear
protein extracts from control hearts (C57BL/6mice) is shown in lanes 4–7. This autoradiogram is representative three separate gel shift experiments for NF-B.
Panel D, scanning densitometry (n 3mice per each group) of the EMSA gels, expressed as arbitrary units of optical density. Columns and bars represent the
mean S.D. *, p 0.05 and **, p 0.01, male versus female; °°, p 0.01, control versus diabetic mice.
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It is likely that acutely (such as in the in vitro model of high
insulin concentrations) insulin stimulates growth through the
same PI3K/Akt pathway by which it mediates glucose uptake.
However, chronically, such as the in db/dbmice, where insulin
resistance and decreased glucose uptake through a down-reg-
ulation of PI3K/Akt pathway are present, hyperinsulinemia
may stimulate growth through an alternative pathway, by
increasing myocardial Akt-1 activation.
Increased circulating levels of pro-inflammatory cytokines,
such as interleukin (IL)-6 (57) and tumor necrosis factor
(TNF)- (18), aswell as high levels of acute phase reactants (58),
have been found in patients with insulin resistance, obesity and
type 2 diabetes. Low-grade chronic inflammation may play a
role in the pathogenesis of insulin resistance in obesity and type
2 diabetes, as well as in cardiovascular complications of diabe-
tes, including cardiac remodeling and heart failure. We have
previously shown that TNF- synergizes with insulin to induce
NF-B activation and expression of adhesion molecules in
endothelial cells (37–40). The present study demonstrates that
insulin, alone or in combination with low concentrations of
TNF-, can activate the transcription factor NF-B in cardiac
myoblasts. Previous studies usingmyoblast cell lines resulted in
contradictory results concerning the effect of TNF- on the
activation of themyogenic program (59). The present study has
used primary myoblasts, which replicate the properties of car-
diomyocytes more closely than myoblast cell lines (60).
In previous studies, cardiac-specific genetic ablation of
NF-B has been shown to attenuate angiotensin II-induced
hypertrophy (61), which indicates a key role for NF-B in the
induction of cardiac hypertrophy. Here we show that TNF-
cooperates with insulin in enhancing SRF-SRE binding and
inducing the activation of themyogenic program at levels up to
10 ng/ml, a concentration previously shown to evoke signaling
events mediated by TNF- receptor activation in cultured
myocytes without inducing necrotic or apoptotic cell death
(62). TNF- stimulation of the myogenic program and hyper-
trophy appears to involve multiple signaling pathways (63).
TNF- activates NF-B in cardiomyocytes and myoblasts (22),
and inmyoblasts in other studies (62, 63). TNF- stimulation of
the myogenic program through SRF signaling is thus likely to
involve mediation by NF-B. We have indeed also shown that
the NF-B inhibitor PDTC, as well as NF-B silencing attenu-
ate the SRF-SRE binding and the expression of the hypertrophy
marker MHC- upon insulin and TNF- treatment.
Our experiments were carried out in serum-starved culture
conditions (a growth medium supplemented with 2% bovine
serum). SRF responds to serum growth factors (64), and the low
basal activity of SRF observed in our experiments may reflect
the presence of serum growth factors at very low con
centrations.
In conclusion, our study reveals that CHIP constitutes an
anti-hypertrophymediator, and can be a target of insulin in the
induction of hypertrophy. Insulin cooperates with TNF- in
inducing NF-B and SRF-SRE activities. Thus, our data shed
new light on the understanding of the molecular mechanism
through which insulin induces hypertrophy and remodeling
during insulin resistance and hyperinsulinemia in type 2 diabe-
tes. Such studies may help designing strategies to prevent dia-
betic cardiomyopathy (65, 66).
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